## Drug Safety

## Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK

Sieta T. de Vries, PhD<sup>1,2</sup>; Petra Denig, PhD<sup>1</sup>; Adriana Andrić, MD<sup>3,4</sup>; Marina Dimov Di Giusti, MD<sup>3,4</sup>; Alicia Ptaszynska-Neophytou<sup>5</sup>; Linda Härmark, PhD<sup>6</sup>; Peter G.M. Mol, PhD<sup>1,2,7</sup>; on behalf of IMI Web-RADR work package 3b consortium and SCOPE Joint Action work package 4.

<sup>1</sup> University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, The Netherlands

<sup>2</sup> Web-RADR work package 3B

<sup>3</sup> Agency for Medicinal Products and Medical Devices of Croatia (HALMED), Croatia

<sup>4</sup> SCOPE Joint Action work package 4

<sup>5</sup> Medicines and Healthcare products Regulatory Agency, London, UK

<sup>6</sup>Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands

<sup>7</sup> Dutch Medicines Evaluation Board, Utrecht, the Netherlands

## **Corresponding author:**

P.G.M. Mol, PhD E-mail: p.g.m.mol@umcg.nl Phone: +31 (0)50-3617861 Fax +31 (0)50-3617889 **Electronic Supplementary Material Table 5.** Number (%) of patients selecting the different answer options for motives (not) to report adverse drug reactions and P-values for tests of differences across the countries

	Total	Croatia (HR)	Netherlands (NL)	UK	P-value
A. In your opinion, what are the b agency? <sup>1</sup>	enefits of r	eporting side	e-effects direct	ly to the na	ational
I can offer my perspective by	213 (51)	68 (50)	89 (49)	56 (57)	0.487
describing my own experience					
I can contribute to the safety of medicines	353 (85)	115 (85)	144 (80)	94 (95)	0.004 (V=0.16) HR – NL: 0.297 NL – UK: 0.001 HR – UK: 0.012
I can share my experience for the benefit of others	329 (79)	103 (76)	137 (76)	89 (90)	0.011 (V=0.15) HR – NL: 0.938 NL – UK: 0.005 HR – UK: 0.006
I can report independently of healthcare professionals	257 (62)	91 (67)	107 (59)	59 (60)	0.344
I can report side effects that I'm embarrassed to discuss with healthcare professionals	98 (24)	44 (32)	19 (11)	35 (35)	<0.001 (V=0.27) HR – NL: <0.001 NL – UK: <0.001 HR – UK: 0.631
B. What are in your opinion the d agency? <sup>2</sup>	rawbacks of	f reporting s	ide-effects dire	ectly to the	
I do not know how to report	146 (47)	52 (48)	55 (43)	39 (52)	0.439
I do not know what happens with my report after I report	197 (63)	76 (70)	75 (59)	46 (61)	0.160
Reporting is too complicated or time-consuming	73 (23)	27 (25)	16 (13)	30 (40)	<0.001 (V=0.25) HR – NL: 0.013 NL – UK: <0.001 HR – UK: 0.031
There is no direct benefit for me personally from reporting	52 (17)	23 (21)	18 (14)	11 (15)	0.286
I do not want to share my personal data	38 (12)	17 (16)	15 (12)	6 (8)	0.283
I do not want to be contacted after I report	15 (5)	6 (6)	6 (5)	3 (4)	0.886
<sup>1</sup> 1 missing; 7 'none'; <sup>2</sup> 112 'none	e'				